- Protocol Short Name and Number: SWOG S1803 MM Maintenance, 1706
- Protocol Long Name: Phase III Study of Daratumumab (NSC- 791647) + Lenalidomide (LD) or Lenalidomide (L) as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
- Key Personnel
- BMT CTN # 1706 Chair: Parameswaran Hari, MD, MRCP
- BMT CTN # 1706 Protocol Coordinator: Cynthia Smith; csmith@swog.org
- Keywords: Multiple Myeloma, MM, Daratumumab, Lenalidomide, LD, DRAMMATIC, Maintenance
Note: For the SWOG S1803 / BMT CTN 1706 study, the BMT CTN is endorsing the study and providing accrual credit. Centers participate via their NCTN group. BMT CTN Centers will receive both NCTN and BMT CTN accrual credits. The protocol may be accessed through the CTSU website: https://www.ctsu.org/. For questions about the study and how to participate, contact the SWOG protocol coordinator, Cynthia Smith, at csmith@swog.org or the CTSU Help Desk at ctsucontact@westat.com or 1 888 823-5923.